Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study according to : Nasdaq Stock Market

The Network's HIV Vaccine Trial Units are located at leading research institutions in 27 cities on four continents. About the HVTNThe HIV Vaccine Trials Network (HVTN), headquartered at Fred Hutchinson Cancer Research Center in Seattle, Wash., is an international collaboration of scientists and educators searching for an effective and safe HIV vaccine. Amongst highest levels of immune responses ever demonstrated in an HIV vaccine human studyPLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV. Internationally renowned HIV vaccine and prevention researchers lead the units.




Inovio Pharmaceuticals Inc (NASDAQ: INO ) jumped more than 30% this morning in pre-market trading after the biopharma developer said its HIV Vaccine showed some of the highest overall rates of immune response ever demonstrated in a human study for such treatments. The vaccine candidate, PENNVAX-GP, consists of a combination of four HIV antigens designed to cover multiple global HIV strains and generate both an antibody (humoral) immune response as well as a T cell (cellular) immune response to both potentially prevent and treat HIV, the Plymouth Meeting, PA-based company said. INO stock had lost 36% in the last 12 months through the close of trading yesterday. As is the case with many biopharma developers, Inovio doesn't have any commercial products for sale. These preliminary results are from a study supported by the HIV Vaccine Trials Network (HVTN) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) in collaboration with Inovio, the company said in a press release this morning.

Inovio Surrenders Some Early Gains (NASDAQ:INO) After Positive HIV Vaccine Clinical Study

The catalyst for the rally is announcement of a clinical study for a HIV vaccine that had nearly 100 percent immune response. The decline off that high found intraday support at $8.64 and is now back actively trading in the $9.00 handle. Posted-In: Technicals Intraday Update Movers Trading Ideas© 2017 Benzinga.com. Inovio Pharmaceuticals Inc (NASDAQ: INO) facebook/" target="_blank">shares are trading higher by $2.00 (28 percent) at $9.13 in Wednesday's session. The announcement made before the open instigated a spike to $12.00 during pre-market trading, which is a level not seen since November 2014.


collected by :Lucy William
To follow all the new news about

VIRUSES and INFECTIONS